STUDY OF SELF TESTING DIAGNOSTIC DEVICE MARKET

Dissertation Submitted to

The IIHMR University, Jaipur

for the partial fulfillment for the award of the degree of

Master of Business Administration (MBA)

in

Pharmaceutical Management

by

Yash Soni

Under the Supervision and Guidance of

Dr. Akshay Kumar Mishra

2025

IIHMR UNIVERSITY

CERTIFICATE

This is to certify that dissertation titled **STUDY OF SELF-TESTING DIAGNOSTIC DEVICE MARKET** is a record of the research work undertaken by **YASH SONI** in partial fulfillment of the requirements for the award of the degree of MBA (Pharmaceutical Management) from the IIHMR University, Jaipur under my guidance and supervision and her approach to the research study has been sincere, scientific, and analytical.

Faculty Guide:
Dr. AKSHAY KUMAR MISHRA
IIHMR University, Jaipur
Date: 19.06.2025

School Dean:
Dr. Saurabh Kumar Banerjee
IIHMR University, Jaipur
Date: 19.06.2025

DECLARATION BY STUDENT

I hereby declare that this dissertation titled **STUDY OF SELF TESTING DIAGNOSTIC DEVICE MARKET** is the bonafide record of my original research work. I declare that it has not been submitted to any other university or institution for the award of any degree or diploma. Information derived from the published or unpublished work of others has been duly acknowledged in the text.



(Signature)

YASH SONI

Date:

20/06/2025

ABSTRACT

- **TITLE:** STUDY OF SELF TESTING DIAGNOSTIC DEVICE MARKET
- **AUTHOR NAME**: Yash Soni
- **ADVISOR NAME:** Mrs. Megha Maheshwari
- **KEY WORD:** Self-testing, point-of-care, diagnostic devices, home diagnostics, global health, market trends, innovation, regulatory landscape.

The global self-testing diagnostic device market has emerged as a critical component of modern healthcare systems, enabling individuals to monitor and manage their health outside traditional clinical settings. With the rising burden of chronic diseases, aging populations, and the demand for decentralized care, self-diagnostic tools—ranging from glucose monitors to COVID-19 antigen tests—are witnessing substantial growth. The COVID 19 pandemic further accelerated adoption creating permanent shifts in consumer behaviour and regulatory flexibility.

This study explores the comprehensive landscape of the global self testing diagnostic device market analysing its current size projected CAGR, adoption patterns across care settings, innovation hotspots regulatory frameworks, and competitive ecosystem. The remote highlights key drivers such as increase awareness, affordability, government reimbursement support, and mobile health integration. It also investigates major challenges like regulatory variation, accuracy concerns, and limited access in low income regions.

Through a multi dimensional approach encompassing market trends, manufacturer profiles, investment dynamics, and policy analysis, this dissertation provides a strategy overview of the evolving self testing device space. The insights gathered can inform healthcare providers, manufacturers, investors, and policy makers on how to capitalise on future growth opportunities while ensuring equitable and reliable access to diagnostic technology.

5

ACKNOWLEDGEMENT

As I Am Approaching Completion of My Project Report, I Would Like to Take This Opportunity to Acknowledge the Invaluable Contributions to My Study, I Am Grateful While Expressing My Gratitude and Appreciation to My Esteemed Guide **Mrs. Megha Maheshwari** His Unwavering Support, Encouragement and Guidance Have Been Instrumental Incompletion of My Dissertation. Throughout The Dissertation, His Guidance, Discipline, Foresightedness, Insights and Work Ethic Were a Great Source of Inspiration On me.

I Sincerely Thank Him for His Cooperation, Mentorship and Support, Without That It Would Have Been Challenging to Complete My Work Project.

I also want to express my gratitude to **Dr. Akshay Kumar Mishra, an associate professor at IIHMR University's School of Pharmaceutical Management in Jaipur**, for his help during this course. His unwavering belief in me and support have motivated me to work harder.

I Am Also Extend My Thankful to **Mrs. Purvi Bhasin, Shayna Girdhar and Friends**. Their Constant Support, Love and Affection Have Been a Source to Work for Excellence Throughout My Life. They Have Given Me More Than I Could Ask for Their Encouragement, Cooperation and Good Wishes Have Made This Work Possible. Finally, I would like to thank Almighty for giving me the courage and strength to follow my dreams and finish my work.

TABLE OF CONTENT

ACRONYMS

CAGR – Compound Annual Growth Rate

COVID-19 – Coronavirus Disease 2019

CE – Conformité Européenne (European Conformity)

CDSCO – Central Drugs Standard Control Organization (India)

CLIA – Clinical Laboratory Improvement Amendments

D2C – Direct to Consumer

EHR – Electronic Health Record

EUA – Emergency Use Authorization

FDA – Food and Drug Administration (USA)

GDP – Gross Domestic Product

HIV – Human Immunodeficiency Virus

IVD – In Vitro Diagnostics

IVDR – In Vitro Diagnostic Regulation (EU)

KPI – Key Performance Indicator

LMICs – Low- and Middle-Income Countries

M&A – Mergers and Acquisitions

MDR – Medical Device Regulation (EU)

NPS – Net Promoter Score

OTC – Over-The-Counter

R&D – Research and Development

ROI – Return on Investment

STDs – Sexually Transmitted Diseases

TB – Tuberculosis

UK – United Kingdom

USA – United States of America

VC – Venture Capital

WHO – World Health Organization

LIST OF FIGURES

LIST OF TABLES

Chapter 1:
Introduction / background

Overview

Self testing devices, also referred to as home diagnostic devices, allow people to conduct health tests on themselves, assess the findings, and take appropriate action. Numerous home tests such as Pregnancy test, COVID 19 antigen testing and glucose monitors for diabetics, are available based on the results. Since these gadgets are intended for laypeople, they are usually used by people without medical knowledge. Results are given promptly, and samples like blood urine or saliva are frequently needed.

1.1 Background of the Study

Self testing diagnostic devices are tools that allow individuals to perform health assessments at home or outside conventional healthcare environments. These devices encompass a wide array of tests from blood glucose monitors in pregnancy kits to advance molecular diagnostics and wearable biosensors. Their rise reflects broader shifts in healthcare toward decentralisation, digital integration, and patient empowerment.

Historically, diagnostic testing was confined to hospitals or laboratories, requiring trained personnel in clinical infrastructure. However, the development of miniaturized, easy to use, and rapid response diagnostic tools has enabled the democratization of health monitoring. This is especially crucial in low resource settings and during global health emergencies, such as the covid 19 pandemic, where access to timely testing became a cornerstone of containment.

As global healthcare systems seek to reduce costs and improve efficiency, self-testing is gaining traction due to its potential to reduce clinic loads, facilitate early disease detection, and enable personalized healthcare pathways. The World Health organization and national health agencies increasingly support self-testing as part of community and preventive healthcare strategies.

1.2 Need for the Study

Despite the growing presence of self-testing devices in the global market, there is limited academic literature that comprehensively examines their economic, regulatory, and technological landscape on a global scale. This study fills that gap by offering an integrated overview of the industry, covering key trends such as:

- Adoption rates across different healthcare settings
- Impact of innovation and digital health convergence

- Regulatory frameworks and challenges
- Competitive and manufacturing trends

Understanding these components is essential for stakeholders aiming to invest, innovate, or regulate within this fast-evolving market.

1.3 Objectives of the Study

- To analyze the global market size and growth trajectory of self-testing diagnostic devices.
- To evaluate the demand signals driving adoption across different regions and demographics.
- To assess adoption patterns by healthcare setting (home, hospital, ambulatory).
- To examine regulatory, reimbursement, and procurement frameworks impacting market growth.
- To identify leading manufacturers, startups, and product innovations shaping the future.

1.4 Scope of the Study

- This study covers a broad spectrum of self-testing diagnostic devices, including but not limited to:
- Infectious disease test kits (e.g., COVID-19, HIV)
- Chronic disease monitoring tools (e.g., glucose monitors, BP machines)
- Fertility and hormonal tests
- Genetic and metabolic testing kits
- Digital diagnostics with mobile or AI integration
- The scope includes global data but provides focused insights into high-growth markets such as the U.S., EU, India, China, and Latin America.

1.5 Significance of the Study

This report will be of value to:

- Healthcare policymakers designing decentralization strategies

- Medical device companies and digital health startups seeking market opportunities
- Investors evaluating funding prospects in diagnostics
- Public health experts advocating for health equity and acces

CHAPTER 2:
LITERATURE REVIEW

2.1 Introduction

Self-testing diagnostic devices, also referred to as home-use or direct-to-consumer diagnostics, are reshaping healthcare delivery models across the globe. With increasing emphasis on preventive healthcare, patient empowerment, and digital health convergence, there is growing scholarly and commercial interest in these technologies. This chapter reviews existing research on self-testing trends, technology evolution, market adoption, and healthcare impact.

2.2 Market Evolution of Self-Testing Devices

The market has transitioned from simple home pregnancy tests to advanced molecular diagnostic kits, driven by miniaturization, smartphone integration, and pandemic-related urgency. According to Harvard Health Publishing (2022), the surge in home-based testing is largely due to convenience and reduced strain on healthcare systems.

Key Drivers:

- Rising prevalence of chronic diseases (e.g., diabetes, hypertension)
- Pandemics (e.g., COVID-19) accelerating acceptance
- Technological innovation enabling accuracy and user-friendliness

2.3 Role in Decentralized Healthcare

Studies (e.g., WHO, 2021) show that self-testing improves access to diagnosis in underserved areas, facilitates early intervention, and aligns with the decentralization goals of modern health systems.

Advantages include:

- Reduced clinic burden
- Faster diagnosis
- Empowered patient decision-making

2.4 Regulatory and Ethical Considerations

As noted by the European Commission (2022) and US FDA guidelines, while these devices offer benefits, concerns around test misuse, data privacy, and regulatory quality assurance persist. The literature suggests a need for harmonized regulation and better post-market surveillance.

2.5 Innovation and Industry Trends

According to research by McKinsey (2023), AI-driven diagnostic tools, digital sample readers, and multi-condition test kits are rapidly entering markets. Companies like Cue Health and Everlywell are pioneering this shift with integrated platforms.

2.6 Literature Gaps

1. Lack of region-specific data on adoption (e.g., India, Africa)
2. Insufficient long-term clinical outcome studies
3. Limited research on affordability and reimbursement barriers.

CHAPTER 3:
METHODOLOGY

3.1 Research Design

The study follows a descriptive and analytical design to assess current trends, adoption patterns, and industry practices in the global self-testing diagnostic device market.

3.2 Research Objectives Recap

- To evaluate the market size and CAGR of self-testing diagnostics
- To examine regional adoption rates and technology use
- To study the role of investment, innovation, and regulation in market shaping
- To identify key players and product innovations

3.3 Data Collection Methods

- Secondary Data:

Reports from WHO, McKinsey, IBEF, and Frost & Sullivan

Market databases (Statista, Grand View Research)

Academic publications and trade journals

3.4 Sampling Technique

Purposive sampling of experts in diagnostics, manufacturers, and regulators to gain deep qualitative insights.

3.5 Data Analysis Tools

1. Descriptive statistics (for trends and adoption)
2. Graphical representation (pie charts, bar graphs)
3. Thematic analysis (for qualitative responses)

3.6 Limitations of the Study

1. Rapid market changes may affect long-term projections
2. Reluctance of firms to share proprietary data

CHAPTER 4:
MARKET LANDSCAPE

4.1 Global Market Size and CAGR

The global self-testing market is projected to increase at a compound annual growth rate (CAGR) of 8.40% between 2025 and 2030, from an estimated 11.39 billion in 2024. The growing emphasis on individualized healthcare, rapid diagnostics technology improvements, and the growing need for quick and easy diagnostic kits are the main factors propelling the self-testing industry's expansion. Self-tests and kits are used to quickly diagnose a wide range of diseases. Additionally, the use of self-testing devices has increased due to growing awareness of the advantages of early diagnosis and routine monitoring, and the self-testing business is anticipated to gain from an increasing number of new product introductions**.**



This graph shows the upward trend in global market size from 2020 to 2030, indicating increasing adoption of self-testing devices.

With the goal of increasing the rate of diagnosis, the COVID-19 pandemic has increased the demand for and focus on self-testing kits. Numerous organizations have undertaken a variety of initiatives to lower the risk of fatalities, hospitalizations, and serious illness. For example, in January 2024, The Home Test to Treat program was launched by NIH in collaboration with the Administration for Strategic Preparedness and Response

(ASPR). This program will provide free COVID-19 health services, including as at-home rapid tests, home treatments, and telehealth consultations, in a select few regions. It is a virtual community health intervention. These elements support the self-testing sector even more.

Furthermore, the market has benefited from growing financing and expenditures made by many organizations and industry participants for the creation of reliable and innovative diagnostics. For instance, Florida Atlantic University (FAU) approved USD 1.3 million for NIH to develop automated and quick HIV self-kits in January 2022. Additionally, the Central Drugs Standard Control Organization (CDSCO) approved the commercialization of Cervi check, an Indian start-up, in April 2022. The Human Papillomavirus (HPV) is diagnosed with this kit.

Key product segments contributing to this growth include:

- Blood glucose monitors (largest revenue share)
- COVID-19 and respiratory infection kits
- Pregnancy and fertility tests
- Cholesterol and lipid profile kits
- Genetic and cancer risk screening tools



This bar chart showing blood glucose monitors are the dominant segment in self-diagnostics.

4.2 Demand Drivers

Global demand for self-testing diagnostics is shaped by several macro and micro-level signals:

- Aging population: Older adults require regular monitoring for chronic conditions.
- Increase in chronic diseases: Hormonal abnormalities, diabetes, and cardiovascular problems are the main causes.
- Pandemic legacy: COVID-19 normalized self-swabbing and at-home test behavior globally.
- Consumer empowerment: Patients are more proactive, health-aware, and digitally literate.
- Rural & low-access regions: Self-tests bridge the gap in areas lacking labs or clinicians.
- Data integration demand: Patients and providers increasingly value test results syncing with mobile apps or EHRs.

4.3 Adoption Patterns in Different Care Settings

Self-testing device usage varies significantly by care environment:

Care Setting	**Adoption Rate (%)**	**Popular Test Type**
Home-use	~65%	Glucose, COVID-19, pregnancy, HIV, cholesterol
Ambulatory clinics	~20%	Rapid infectious disease kits, HbA1c, ECG
Hospitals	~10%	Emergency-use rapid diagnostics, pre-triage



Home-use is the dominant setting and is expected to increase due to telemedicine, insurance support for self-care tools, and e-commerce accessibility.

4.4 Regional Market Overview

With a 33.40% revenue share in 2024, the North American self-testing market led the world. This high percentage is explained by the rise in chronic illness cases that call for prompt diagnosis, the development of technology in the medical field, and the accessibility of important players. Growing the quantity of new items approved by the FDA also accelerates market expansion. For example, empower DX announced the release of a genetic risk test for coeliac disease that may be taken at home in May 2022. The kits do molecular testing and yield precise findings.

U.S.: largest market share; fuelled by robust insurance infrastructure, high prevalence of chronic diseases, and regulatory approvals. In 2024, the U.S. self-testing market accounted for a sizeable portion of the North American market. High health awareness, sophisticated healthcare infrastructure, and the rising incidence of chronic diseases like diabetes and hypertension are all factors contributing to this significant proportion The Industry is also profited from the growing use of digital health and telemedicine, which has increased demand for at home diagnostic kits. Furthermore, the availability of FDA approved self testing kits in the ease of Internet distribution channels have solidified the United States position as the industry leader in this field.

Europe: Fast growing yet heavily regulated, nations like Germany and the UK have formalised self testing regimes. Over the course of the forecast period, The Europe Self Testing Market is expected to grow significantly.Government initiatives that promote preventative care or propel growth are responding to the growing demand from

consumers for easily available healthcare solutions. Because chronic diseases like cancer and cardiovascular disorders are becoming more common, self-testing kits are being used more often for early detection and monitoring. The increasing use of at home diagnostics in European nations due to technological developments has also been a major factor in the markets growth.

Over the course of the forecast period, The **UK** self testing market is expected to develop significantly, mostly as a result of increased health awareness in national health service (NHS) programmes that support self monitoring and early diagnosis. The use of self testing solutions especially for infectious diseases, was greatly boosted by the covid 19 pandemic.

Over the course of the forecast period, The **Germany** Self Testing Market is expected to grow significantly due to the strong healthcare policies that have further strengthened the market in the high adoption rates of cutting edge self diagnostic equipment. The market is growing because of Germany's ageing population and rising rate of chronic illnesses, which have increased demand for trustworthy and easy to use self testing solutions.

China and India are increasing their domestic manufacturing in the **Asia-Pacific** region, which has a lot of potential, with government incentives. The self-testing market in Asia Pacific is anticipated to expand at the quickest rate during the projected period. Government initiatives to reduce the burden of disease, the advancement of the healthcare system, and the rise in activities related to the study and creation of innovative treatments for infections are the main factors driving the growth of the regional market. Throughout the forecast period, the Asia Pacific Self Testing Industry is anticipated to be influenced by a number of additional variables, such as the expansion of healthcare infrastructure, developing healthcare reforms, population growth, the prevalence of chronic diseases, and the influx of local businesses. The urgent need for self testing kits necessitates the use of easily accessible and effective diagnostic instruments, especially in nations with high illness prevalence like Thailand.

Over the course of the forecast period, The **China** Self Testing Market is expected to increase significantly due to the country's huge population, rising health consciousness, and rising prevalence of chronic illnesses including diabetes and cardiovascular ailments. Market demand has also been fuelled by government programmes to increase access to healthcare and encourage early diagnosis. Furthermore, a key factor in the development of the market has been the accessibility of reasonably priced self-testing kits in the swift growth of e-commerce platforms.

During the projected period, the **Japanese** self-testing market is expected to rise significantly. driven by the nation's high rates of modern technology adoption and emphasis on preventive healthcare. Additionally, the industry is being driven by innovation due to Japan's robust healthcare system and consumer preference for accurate, user-friendly diagnostic instruments.

The market for self-testing in **India** is expanding due to important health issues, such as the increasing incidence of illnesses including dengue and fever, of which there were around 300,000 cases in 2023. Many cases go undiagnosed until symptoms develop,

despite the fact that early diagnosis is crucial to preventing serious sequelae. Self-testing solutions are clearly becoming more and more necessary in India since they offer a quick and easy approach to identify health problems and assist people in managing them before they worsen. Additionally, almost 30% of Indian women get UTIs, which can cause major health issues like kidney damage if left untreated. Furthermore, if left untreated, the increase in early menopause, which can start as early as age 40, can cause anxiety and sadness. In order to solve these problems, producers like Humanity Pharma provide RAPID NEWS self-test kits, which are easily accessible and user-friendly solutions for early menopause and dengue UTI detection, enabling people to test discreetly and accurately at home.

Saudi Arabia's self-testing market is distinguished by a dynamic regulatory environment, increasing competition, and quick innovation. Self-diagnostic tools have become more popular as a result of the government's Vision 2030 effort, which aims to modernise the healthcare industry and encourage preventive treatment. A tech-savvy populace, rising healthcare spending, and a strong emphasis on localised production to satisfy rising demand are all helping the industry.



This chart showing market distribution. North America and Europe lead, but Asia-Pacific is growing.

4.5 Market Challenges

Although self test devices have many advantages, there are also certain drawbacks to take into account. They might not always be as accurate as tests carried out in a medical setting to start. Mismanagement of a medical issue may result from the potential for false positives or negatives. Furthermore, not all medical disorders can be adequately monitored by self test devices. If the problem is severe or complicated, the healthcare provider must still be consulted.

Despite rapid growth, several barriers persist:

- Accuracy & reliability concerns for complex conditions
- Regulatory fragmentation across countriesand regions
- Digital literacy gaps, especially among elderly or rural populations
- Cost burden in lower income segment without reimbursement

CHAPTER 5:
INDUSTRY DYNAMICS

5.1 Investment Activity in Self-Testing Diagnostics

Over the last five years, the self testing diagnostics segment has seen exponential growth in venture capital, private equity, and strategic M & A activity. Key drivers include pandemic preparedness, consumer health tech adoption, and the rising demand for decentralised care.

Major Investment Trends (2020–2024):



This line graph highlight growing investor interest in self diagnostic technologies.

VC funding: Startups like LetsGetChecked, and Thriva have raised over $1.5 billion collectively, focusing on at home diagnostics for wellness, sexual health, and chronic

conditions.

Strategic acquisitions: Abbott acquired Alere to strengthen its point of care portfolio, siemens healthiness invested heavily in rapid diagnostics.

Public Markets: Several firms, entered IPOs post-COVID as investors recognized the potential of self-testing platforms.

5.2 Innovation Hubs

Geographically, several countries have become R&D hubs for diagnostic innovation:

Country/Region	Innovation Hotspot	Key Innovations
USA	Molecular diagnostics, digital health integration	Teal Health: At-home self-collection kits for cervical cancer and HPV screening. Sherlock Biosciences: **CRISPR-based molecular diagnostics** for **STIs** like chlamydia and gonorrhea
Europe	Precision diagnostics, regulatory excellence	Roche Accu-Chek: Glucose self-monitoring Siemens Healthineers: POC diagnostic platforms - Strong compliance with EU MDR
UK	Decentralized testing, digital diagnostics	SureScreen Diagnostics: COVID-19 lateral flow - Thriva Subscription blood test kits TestCard: Smartphone-based urine diagnostics
China	caled manufacturing, digital health distribution	iHealth: FDA-authorized self-tests - Lepu & Wondfo: High-volume teral flow kits WeDoctor & Ping An: App-linked home testing
India	Affordable rapid test kits, large-scale domestic production	MyLab CoviSelf: Home COVID-19 kits (ICMR-approved) - HealthCube: AI-powered rural diagnostics - TataMD: Rapid antigen & health kiosk solutions
UAE	AI-led health innovation, genomics & screening	G42 Healthcare: AI-based self-testing platforms - Pure Health & Tamouh: Scaled COVID-19 self-test implementation - DHA: Digital pilot programs

Technological innovations include:

- Multiplex testing (one device, multiple disease detection)
- App-enabled lateral flow readers
- AI-powered symptom tracking and test interpretation

5.3 Procurement & Reimbursement Landscape

Procurement Models:

- Public health procurement via national health agencies (e.g., NHS UK, Indian Ministry of Health)
- Private e-commerce sales channels (Amazon, company D2C platforms)
- Pharmacy chains and health insurers stocking approved kits

Reimbursement Trends:

- USA: Medicare covers glucose monitors, COVID-19 kits, and some STI tests; employer-sponsored plans expanding coverage.
- Germany & France: Reimbursement available for HIV self-tests and pregnancy kits under statutory schemes.
- India: Mostly out-of-pocket; government schemes cover tests like HIV, TB, and maternal health via NGOs or public supply chains.

5.4 Emerging Regulatory Landscape

Self-testing devices are subject to varying levels of regulation across markets. Global trends indicate a move toward risk-based classification, digital regulation, and post-market surveillance.

Country/Region	**Regulatory authority**	**Key regulation**
USA	Food and drug administration (FDA)	510(k) clearance for premarket notification - Emergency Use Authorization (EUA) for COVID-19 tests - CLIA waiver for home-use devices
Europe	EMA / European Commission, MDR/IVDR	In Vitro Diagnostic Regulation (IVDR) 2017/746 effective from May 2022 - CE marking mandatory - Enhanced post-market surveillance
UK	Regulatory Agency for Medicines and Healthcare	Devices regulated under UK MDR 2002 (amended post-

	Products (MHRA)	Brexit) - Registration required for all IVDs - CE or UKCA marking
China	National Medical Products Administration (NMPA)	Classifies self-test devices under IVD Class II or III - Requires local clinical trials for foreign manufacturers - Online filing and approval system
India	Central Drugs Standard Control Organization (CDSCO)	Medical Device Rules (MDR) 2017 classify self-testing kits as "moderate risk" (Class B) - Form MD-14 approval required for import - Licensing through SUGAM portal
UAE	The Dubai Health Authority (DHA) and the Ministry of Health and Prevention (MOHAP)	IVDs and self-testing kits require import registration and approval under Cabinet Decision No. 22/2021 - Digital health integration promoted under Dubai Health Strategy

Key Challenges:

- Harmonizing global standards for self-testing approvals
- Ensuring quality assurance of e-commerce-sold test kits
- Balancing innovation with patient safety

CHAPTER 6:
COMPETITIVE & INNOVATION ANALYSIS

6.1 Top Manufacturers & Exporters

Several established medical technology firms dominate the self-testing market globally. These players bring robust distribution networks, regulatory compliance, and R&D capabilities.

Key Self- Testing Companies:

Below is a list of the leading companies in the self-testing sector. Collectively, these companies dominate the market and determine the industry's course.

- Geratherm Medical AG
- Cardinal Health
- OraSure Technologies, Inc.
- bioLytical Laboratories Inc.
- PRIMA Lab SA.
- BD
- F. Hoffmann-La Roche Ltd.
- Bionime Corporation
- Abbott.

6.2 Regional Manufacturing Dynamics

Countries are ramping up domestic manufacturing of self-diagnostic kits for economic, logistical, and public health security reasons.

India: Over 30 local firms produce rapid kits under CDSCO license. COVID-19 and TB kits are widely manufactured under the “Make in India” initiative.

China: Massive production of antigen kits, glucose monitors, and export-focused lateral flow devices.

Brazil & South Africa: Public-private partnerships are driving local test kit manufacturing for HIV and maternal care.

Benefits include:

- Faster regulatory clearance
- Supply chain resilience
- Cost control and job creation

6.3 Startups & Market Disrupters

Numerous startups are reshaping the self-testing ecosystem with app-enabled solutions, subscription models, and wellness-focused diagnostics.

Startups name	**Country/Region**	**Focus area**
Teal Health , Sherlock Biosciences	USA	• At-home self-collection kits for **cervical cancer** and **HPV screening.** • **CRISPR-based molecular diagnostics** for **STIs** like chlamydia and gonorrhea
Thriva	UK	• Personalized home health tests with live dashboard & health tracking
HealthCube	India	• AI-powered portable diagnostic boxes used in rural and semi-urban areas
iHealth Labs **,** Lepu Medical	China	• Self-monitoring kits for COVID-19, BP, glucose, and integration with apps • COVID-19 and chronic disease rapid test kits with CE & NMPA certification
G42 Healthcare **,** Pure Health	UAE	• AI-led diagnostics, genomics, and mass testing initiatives (COVID-19 etc.) • One of the largest diagnostic networks; supports home test accessibility

6.4 Product Innovations

The self-testing landscape is rapidly evolving with advanced technology integrations:

- AI-enabled test readers that interpret results with smartphone cameras.
- Multiplex kits capable of detecting multiple conditions in a single sample.
- Connected diagnostics that auto-sync with patient apps and provider dashboards.
- Wearable integration: Devices like smartwatches now incorporate sensors for glucose, heart rate, and oxygen levels

CHAPTER 7:
FINDINGS, RECOMMENDATIONS & CONCLUSION

7.1 Summary of Key Findings

From this comprehensive review of the global self-testing diagnostic device market, the following insights have emerged:

Strong Market Growth: The market is valued at over USD 34 billion and is growing at a CAGR of ~8.3%, with home-use devices leading the way.

Demand Drivers: Aging population, chronic diseases, and pandemic-led behavior shifts are fueling adoption.

Dominance of Home-Use: Over 60% of self-testing occurs at home, supported by digital apps and consumer convenience.

Investment Momentum: Venture capital and M&A activity are accelerating, especially around digital-first diagnostics.

Innovation Hotspots: The US, Germany, India, and Israel lead in device innovation, biosensors, and AI applications.

Startups Reshaping the Market: Disruptive players like Teal Health , Sherlock Biosciences and LetsGetChecked are redefining access, speed, and personalization.

Regulatory Complexity: Markets are governed by varied frameworks (FDA, CE, CDSCO, IVDR), which can delay cross-border scalability.

Manufacturing Push: Countries are localizing production for supply chain security and cost efficiency.

Product Innovation: Devices are becoming smaller, more intelligent, and integrated with mobile platforms for real-time monitoring and alerts.

7.2 Strategic Recommendations

For Policymakers:

Harmonize Regulatory Frameworks: Streamline cross-border approvals through mutual recognition agreements.

Subsidize Essential Self-Tests: Especially for chronic diseases and maternal health in LMICs (low- and middle-income countries).

Promote Local Manufacturing: Extend incentives under national health programs to domestic test kit producers.

For Industry Stakeholders:

Invest in digital experience: Ensure that self tests come with intuitive apps, tutorials and multilingual instructions.

Focus on multiplex testing: Develop kits that can screen for multiple conditions from a single sample.

Forge partnerships: Collaborate with pharmacies, insurers, and digital health platforms for bundled offerings.

For Healthcare Providers:

Integrate self test data: Use wearable and home test data to personalise treatment plans.

Educate patients: Train users on proper usage, interpretation, and when to seek professional support.

7.3 Conclusion

A global self testing diagnostic device market is not just an industry trend it represents a paradigm shift in the way health care is accessed, delivered, and experienced. In the face of increasing disease burdens, overstretched health systems, and rising demand for personalised care, self diagnostics are emerging as a pivotal component of future ready healthcare infrastructures.

This dissertation has explored the full spectrum of the self testing ecosystem, revealing how home based diagnostics are transforming from niche convenience tools into essential elements of global health strategies. From glucose monitors to AI enabled covid 19 tests, these devices are redefining the relationship between the patient and the provider by decentralising diagnostics, reducing time to diagnosis, and promoting self awareness in early intervention.

The Rapid uptake of self tests during the Covid 19 pandemic showcased their value not only in individual health management but also in supporting public health surveillance. This event served as a global test case, normalising at home testing behaviour and catalysing regulatory, technological, and behavioural changes that are expected to outlast the pandemic itself.

However, growth is not without challenges. Regulatory inconsistencies across countries, disparities in access, concerns about data security, and gaps in user education could hinder the full realisation of the market's potential. To overcome these barriers, collaboration among device manufacturers, digital health companies, regulators and public health authorities is essential.

The future of the self testing diagnostics industry lies in convergence with diagnostics, digital health, wearables, telemedicine, and AI all integrating to provide a seamless and continuous care experience. Innovations in multiplex testing, connected biosensors and personalised digital dashboards will allow users to monitor multiple conditions simultaneously, receive actionable feedback, and communicate results to healthcare professionals in real time.

In conclusion, self testing diagnostic devices are no longer supplementary tools but essential assets for 21st century healthcare. By empowering individuals, easing pressure on formal healthcare systems, and enabling timely interventions, they contribute to more inclusive, efficient, and resilient global health systems. Ensuring their accuracy, affordability and accessibility, and accessibility will determine their role in achieving universal health coverage and improving population health outcomes in the years to come.

REFERENCES

- https://www.grandviewresearch.com/industry-analysis/self-testing-market-report
- https://www.bio-standards.com/blog/self-test-devices-a-growing-trend-in-healthcare-sfda
- https://www.coherentmarketinsights.com/market-insight/self-testing-market-4902
- https://www.imarcgroup.com/india-self-testing-kits-market
- Abbott. Panbio COVID-19 Antigen Self-Test. Abbott Laboratories, 2023. https://www.globalpointofcare.abbott/en/product-details/panbio-covid-19-ag-home-test.html
- Bio-Rad Laboratories. Diagnostic Testing Solutions. Bio-Rad, 2023. https://www.bio-rad.com/en-us/category/diagnostics?ID=LUSO0MZY
- Buttle, Francis. Customer Relationship Management: Concepts and Technologies. Elsevier, 2009. https://www.researchgate.net/publication/286198853_Customer_relationship_management_concepts_and_technologies
- Chaffey, Dave, and Fiona Ellis-Chadwick. Digital Marketing. Pearson Education, 2019. https://www.pearson.com/en-us/subject-catalog/p/digital-marketing/P200000003911/9781292241579
- Cue Health. Cue COVID-19 Test. Cue Health Inc., 2023. https://www.cuehealth.com/products/covid-19/
- Everlywell. Home Health Tests. Everlywell Inc., 2023. https://www.everlywell.com/
- Gartner. “3 Trends Reshaping B2B Marketing.” Gartner, 2021. https://www.gartner.com/en/articles/3-trends-reshaping-b2b-marketing
- HealthCube. Point-of-Care Diagnostics Platform. HealthCube India, 2023. https://healthcube.in/
- India Brand Equity Foundation (IBEF). Indian Pharmaceutical Industry

Report. IBEF, 2023. https://www.ibef.org/industry/pharmaceutical-india.aspx

- LetsGetChecked. At-Home Health Testing Kits. LetsGetChecked, 2023. https://www.letsgetchecked.com/
- LinkedIn B2B Institute. The State of B2B Marketing. LinkedIn, 2022. https://business.linkedin.com/marketing-solutions/b2b-institute
- McKinsey & Company. "Future of Pharma Operations." McKinsey & Company, 2021. https://www.mckinsey.com/industries/life-sciences/our-insights/future-of-pharma-operations
- myLAB Box. At-Home STD and Health Tests. MyLAB Box, 2023. https://www.mylabbox.com/
- Roche Diagnostics. Accu-Chek and COVID-19 Tests. Roche, 2023. https://www.roche.com/products/product-list.htm
- Siemens Healthineers. Diagnostics Portfolio. Siemens AG, 2023. https://www.siemens-healthineers.com/diagnostics
- Thriva. Personalized At-Home Blood Testing. Thriva Ltd., 2023. https://thriva.co/
- World Health Organization (WHO). Prequalification of In Vitro Diagnostics (IVDs). WHO, 2023. https://extranet.who.int/pqweb/vitro-diagnostics